COVID-19 is impacting to a greater extent the patients having underlying metabolic impairments (diabetes mellitus and/or obesity), as WHO is pointing out. On the other hand, increased levels of inflammatory markers cytokines with pro-inflammatory outcomes constitute predictors of adverse outcome in COVID-19 patients (Skalny et al., 2020).